34

Lupi R, Pulizzi N, Rita M, Marchetti P, Del Prato S. Mechanisms of beta-cell destruction: Insulin resistance and inflammation in diabetes progression. Medicina Clinica Monografias 2007; 8(1):9-17. [More details]

33

Ouali K, Trea F, Toumi L, Bairi A, Maurel D, Guellati MA. Hesperidine, a flavonoid antioxidant decrease oxidative stress and prevent fœtal malformations in experimental diabetic pregnancy. Phytotherapie 2007; 5(4):204-9. [More details]

32

Hayden MR, Karuparthi PR, Habibi J, Wasekar C, Lastra G, Manrique C, et al. Ultrastructural islet study of early fibrosis in the Ren2 rat model of hypertension. Emerging role of the islet pancreatic pericyte-stellate cell. JOP. J Pancreas (Online) 2007; 8(6):725-738. [More details]

31

Hayden MR, Sowers JR. Isletopathy in Type 2 diabetes mellitus: implications of islet RAS, islet fibrosis, islet amyloid, remodeling, and oxidative stress. Antioxid Redox Signal 2007; 9(7):891-910. [More details]

30

Hayden MR, Karuparthi PR, Manrique CM, Lastra G, Habibi J, Sowers JR. Longitudinal ultrastructure study of islet amyloid in the HIP rat model of type 2 diabetes mellitus. Exp Biol Med (Maywood) 2007; 232(6):772-9. [More details]

29

Gong W, Liu ZH, Zeng CH, Peng A, Chen HP, Zhou H, Li LS. Amylin deposition in the kidney of patients with diabetic nephropathy. Kidney Int 2007; 72(2):213-8. [More details]

28

Sartoretto JL, Oliveira MA, Nigro D, Carvalho MH, Tostes RC, Fortes ZB. Constrictor responses to noradrenaline, hemodynamic profile, and superoxide levels measured by hydroethidine oxidation in diabetic rats. Biol Pharm Bull 2007; 30(10):1938-42. [More details]

27

Standl E. The importance of beta-cell management in type 2 diabetes. Int J Clin Pract Suppl 2007; (153):10-9. [More details]

26

Campbell IW, Mariz S. Beta-cell preservation with thiazolidinediones. Diabetes Res Clin Pract 2007; 76(2):163-76. [More details]

25

Wlaschitz S. The Equine Metabolic syndrome. Wiener Tierarztliche Monatsschrift 2007; 94(1-2):10-15. [More details]

24

García A, Xu S, Dewhirst FE, Nambiar PR, Fox JG. Enterohepatic Helicobacter species isolated from the ileum, liver and colon of a baboon with pancreatic islet amyloidosis. J Med Microbiol 2006; 55(Pt 11):1591-5. [More details]

23

Hayden MR, Sowers JR. Hypertension in type 2 diabetes mellitus. Insulin 2006; 1(1):22-37. [More details]

22

Waine C. Obesity and type 2 diabetes. Nutrition Bulletin 31 (2), pp. 111-114 [More details]

21

Coppock DL, Thorpe C. Multidomain flavin-dependent sulfhydryl oxidases. Antioxid Redox Signal 2006; 8(3-4):300-11. [More details]

20

Sampathkumar R, Balasubramanyam M, Tara C, Rema M, Mohan V. Association of hypoglutathionemia with reduced Na(+)/K(+) ATPase activity in type 2 diabetes and microangiopathy. Mol Cell Biochem 2006; 282(1-2):169-76. [More details]

19

Colombo M, Kruhoeffer M, Gregersen S, Agger A, Jeppesen P, Oerntoft T, Hermansen K. Energy restriction prevents the development of type 2 diabetes in Zucker diabetic fatty rats: coordinated patterns of gene expression for energy metabolism in insulin-sensitive tissues and pancreatic islets determined by oligonucleotide microarray analysi?. Metabolism 2006; 55(1):43-52. [More details]

18

Aoun P, Albrecht III CR, Gambert SR. Diabetes mellitus: Present and future preventive strategies - Part II. Clinical Geriatrics 2005; 13(7):30-5. [More details]

17

Margina? D, Vla?dica M, Da?nciulescu R, Gra?dinaru D, Mitrea N. Clinical study regarding the influence of hygieno-dietetic regimen on hyperglycemic overweight patients. Archives of the Balkan Medical Union 2005; 40(3):162-5. [More details]

16

Hayden MR, Whaley-Connell A, Sowers JR. Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. Am J Nephrol 2005 -; 25(6):553-69. [More details]

15

Hayden MR, Tyagi SC, Kerklo MM, Nicolls MR. Type 2 Diabetes Mellitus as a Conformational Disease. JOP. J Pancreas (Online) 2005; 6(4):287-302. [More details]

14

Walter H, Lubben G. Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus. Drugs 2005; 65(1):1-13. [More details]

13

Davi G, Falco A, Patrono C. Lipid peroxidation in diabetes mellitus. Antioxid Redox Signal 2005; 7(1-2):256-68. [More details]

12

Hayden MR, Tyagi SC. Neural redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic neuropathy. Med Sci Monit 2004; 10(12):RA291-307. [More details]

11

Hayden MR, Tyagi SC. Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: The pleiotropic effects of folate supplementation. Nutr J 2004; 3(1):4. [More details]

10

Del Prato S, Wishner WJ, Gromada J, Schluchter BJ. Beta-cell mass plasticity in type 2 diabetes. Diabetes Obes Metab 2004; 6(5):319-31. [More details]

9

Brennan AL, Geddes DM, Gyi KM, Baker EH. Clinical importance of cystic fibrosis-related diabetes. J Cyst Fibros 2004; 3(4):209-22. [More details]

8

Waine C. The Metabolic Syndrome. The National Obesity Forum E-book. [More details]

7

Tseng CH. The potential biological mechanisms of arsenic-induced diabetes mellitus. Toxicol Appl Pharmacol 2004; 197(2):67-83. [More details]

6

Urusova IA, Farilla L, Hui H, D'Amico E, Perfetti R. GLP-1 inhibition of pancreatic islet cell apoptosis. Trends Endocrinol Metab 2004; 15(1):27-33. [More details]

5

Hayden MR, Tyagi SC. Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol 2003; 2(1):2. [More details]

4

Hayden MR, Tyagi SC. Myocardial redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and congestive heart failure. Med Sci Monit 2003; 9(7):SR35-52. [More details]

3

Wiernsperger NF. Oxidative stress as a therapeutic target in diabetes: revisiting the controversy. Diabetes Metab 2003; 29(6):579-85. [More details]

2

Hayden MR, Tyagi SC. Intimal redox stress: accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol 2002; 1(1):3. [More details]

1

Hayden MR. Islet Amyloid, Metabolic Syndrome, and the Natural Progressive History of Type 2 Diabetes Mellitus. JOP. J Pancreas (Online) 2002; 3(5):126-138. [More details]